Our Campaign

Welcome to the
Do You C Us? campaign

About Us

Despite the name, rare and less common cancers account for nearly half of new cancer diagnoses1

They affect people of all ages, genders, ethnicities and locations. However, the nature of these conditions means that people can often face a range of issues, such as recognising symptoms, obtaining a diagnosis, receiving the most suitable treatment or getting appropriate levels of support.

‘Do You C Us?’ aims to unite Pfizer, Cancer52 and its member charities to raise awareness of the challenges facing people living with rare and less common cancers and highlight the need for change to address these.

a man and woman smiling
icon of a cancer cell

Although 47% of cancers diagnosed in England are rare or less common, 55% of people die from these cancers.

Cancer52 (2020) Getting a Better Deal for Rare and Less Common Cancers.

icon of people

Approximately 144,600 people in England are diagnosed with a rare or less common cancer every year.

Cancer52 (2020) Getting a Better Deal for Rare and Less Common Cancers.

The UK

The total number of people living with a rare or less common cancer in the UK is estimated to grow to 2.06 million by 2040

Br J Cancer 2012;107:1195-202 doi: 10.1038/bjc.2012.366. Maddams J, Utley M, Moller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. 

Resources

Find out more about rare and less common cancers, and discover helpful resources here: